FDA Approves Esketamine Nasal Spray (Spravato™) for Treatment-Resistant Depression

Earlier this month, the Food and Drug Administration (FDA) approved esketamine nasal spray, which will be marketed by Johnson & Johnson (J&J) under the trade name of Spravato™. Spravato is approved for use in conjunction with an oral antidepressant for treatment-resistant depression. The term “treatment-resistant” refers to those patients who have failed to achieve relief […]

Read more detail on Recent Health Care Law posts –

This entry was posted in Health Law and tagged , . Bookmark the permalink.

Leave a Reply